Scienture Holdings, Inc. Common Stock (SCNX) is a publicly traded Healthcare sector company. As of July 9, 2026, SCNX trades at $0.33 with a market cap of $14.04M and a P/E ratio of -0.12. SCNX moved +0.18% today. Year to date, SCNX is -35.02%; over the trailing twelve months it is -79.42%. Its 52-week range spans $0.24 to $8.72. Analyst consensus is buy with an average price target of $1.50. Rallies surfaces SCNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Scienture Ships 10 mg REZENOPY Nasal Spray to Wholesalers, Targets $144M Market: Scienture completed manufacturing of commercial inventory for its 10 mg REZENOPY nasal spray and will begin U.S. wholesaler shipments in July, targeting an August launch. The highest-dose FDA-approved naloxone spray enters a $144 million market with nearly 9.8 million annual units and coverage for 100 million lives.
| Metric | Value |
|---|---|
| Price | $0.33 |
| Market Cap | $14.04M |
| P/E Ratio | -0.12 |
| EPS | $-2.70 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.72 |
| 52-Week Low | $0.24 |
| Volume | 7.28M |
| Avg Volume | 0 |
| Revenue (TTM) | $431.61K |
| Net Income | $-41.51M |
| Gross Margin | 76.80% |
1 analysts cover SCNX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $1.50.